Serves as lead trial counsel in patent infringement, trade secrets, and invalidity litigation across multiple federal jurisdictions
Counsels clients on overall intellectual property strategy and positioning, including litigation avoidance
Provides strategic IP guidance in complex transactions where intellectual property assets are critical to the deal
Advises clients across pharma/biotech, internet, semiconductor, hardware and software, medical device, and manufacturing industries
Sarah Chapin Columbia is a Fellow of the American College of Trial Lawyers. Over the last dozen years, she has led 17 patent infringement, trade secrets, and invalidity trials (11 jury trials and six bench trials) across several jurisdictions, including the federal courts in Massachusetts, Florida, Delaware, Colorado, California, and Texas.
- Lead counsel for Alnylam in ongoing patent infringement litigation involving the cationic lipids essential to the delivery of the COVID-19 vaccines (Alnylam v. Pfizer/BionTech (D. Delaware); Alnylam v. Moderna (D. Delaware))
- Lead counsel for Next Caller in simultaneous patent infringement litigation and trade secrets, tortious interference and breach of contract litigation related to authentication services. Successfully secured a unanimous jury verdict in favor of Next Caller in both matters (TrustID Inc. v. Next Caller Inc., (D. Delaware), TRUSTID, Inc. v. Next Caller Inc., (D. Colorado))
- Lead counsel for Amgen in a patent infringement action and jury trials involving breakthrough biologic therapy for the treatment of high LDL cholesterol (Amgen v. Sanofi, et al., (D. Delaware))
- LMG Life Sciences, Shortlisted, General Patent Litigator of the Year – New England – 2026
- Chambers USA, Intellectual Property, Band 1 (Massachusetts) and Band 3 (Nationwide), 2008-2026; Life Sciences, Band 3 (Massachusetts), 2026
- The Best Lawyers in America, Lawyer of the Year in Boston: Litigation – Intellectual Property, 2022 and 2024-2026
- The Sedona Conference®, Working Group on Patent Damages and Remedies
- Harvard Law School, JD, magna cum laude
- Harvard University, MPP
- Wesleyan University, BA, Economics
- Massachusetts
- Supreme Court of the United States
- US Court of Appeals for the Federal Circuit
- US Court of Appeals for the First Circuit
- US Court of Appeals for the Second Circuit
- US Court of Appeals for the Ninth Circuit
- English

Richard C. Call
Richard C. Call focuses his practice on a broad range of state and local tax matters, including litigation, advisory, and transactional work. He represents clients in proceedings before administrative bodies, trial courts, and appellate courts across multiple jurisdictions.
- Successfully led a team seeking federal review of a New York City Unincorporated Business Tax case in 2025, arguing that the Tax Injunction Act did not bar federal review due to a lack of judges at the New York City Tax Appeals Tribunal, Administrative Judge Division
- Successfully argued before the Massachusetts Appeals Court in Bay State Gas Company v. Commissioner, securing a rare reversal of the Massachusetts Appellate Tax Board in a corporate income tax case
- Best Lawyers in America, Tax Law, Boston, 2022–2027
- Massachusetts Lawyers Weekly, Go To Tax Lawyer, 2024
- Legal 500 US, 2021–2024
- Super Lawyers, New York-Metro Rising Star, 2013–2014
- Super Lawyers, Massachusetts Rising Star, 2018
- New York University School of Law, LLM
- Brigham Young University J. Reuben Clark Law School, JD
- Brigham Young University, BA
- Massachusetts
- New York
- English

Brian M. Bunn
Brian M. Bunn represents clients in the full range of corporate transactions and financings, including mergers, stock and asset purchases and sales, venture capital investments, joint ventures, restructurings and recapitalizations. Brian has deep experience in the life sciences, healthcare, medical device and technology fields. He also advises clients with interests and operations in the food and beverages, energy and manufacturing industries, among other sectors. Brian leads the Boston corporate practice.
- Legal 500 US, Recommended, 2024
- Acritas Stars 2020 listed among independently rated lawyers
- Boston Bar Association
- Massachusetts Bar Association
- Boston University School of Law, JD, cum laude
- Hamilton College, BA, cum laude
- Massachusetts
- English

Charles R. Buck
Advises hospital systems, academic medical centers, faculty practice groups, ACOs, and health insurers on complex transactions and regulatory compliance
Handles mergers and acquisitions, joint ventures, strategic affiliations, and conversions to tax-exempt status in the healthcare sector
Counsels clients on federal fraud and abuse laws, including the Stark Law, and state regulatory matters
Advises on physician alignment, HMO regulatory matters, and healthcare organizational strategy
Charles (Charlie) R. Buck advises healthcare enterprises on complex transactions and regulatory compliance. He represents a wide range of clients, including hospital and health systems, academic medical centers and faculty practice groups, accountable care organizations, and health maintenance organizations (HMOs) and other health insurers.
- Advised Lahey Health System on its consolidation with Beth Israel Deaconess Medical Center, New England Baptist Hospital, Mount Auburn Hospital, and Anna Jaques Hospital to form Beth Israel Lahey Health, the most significant healthcare transaction in the Massachusetts market since the formation of Partners HealthCare in 1994
- Advised Reliant Medical Group in the sale of its assets and operations to OptumCare, a division of UnitedHealth Group
- Advised RWJBarnabas Health in the negotiation of a long-term academic and clinical affiliation with Rutgers University
- Advised Dana-Farber Cancer Institute on the establishment of several community-based facilities
- Advised sophisticated medical oncology group on its acquisition by American Oncology Network (AON)
- Chambers USA, Band 1 in Healthcare, 2006-2026
- The Best Lawyers in America, Healthcare Law, 2008-2027
- Massachusetts Lawyers Weekly, Go To Life Sciences/Health Care, 2026
- Thomson Reuters, Stand-out Lawyer – independently rated lawyers, 2024-2026
- The Best Lawyers in America, Lawyer of the Year in Boston: Healthcare Law, 2015, 2018, 2022 and 2025
- Legal 500 US, Recommended, 2015-2019 and 2024
- McDermott Will & Schulte, Boston Health Industry Advisory Practice Group, partner-in-charge
- McDermott Will & Schulte, Hospitals and Health Systems Practice Group, co-leader
- Stanford Law School, JD, Order of the Coif
- Middlebury College, BA, magna cum laude
- Massachusetts
- English

Stephen W. Bernstein
Stephen W. Bernstein specializes in e-health, “big data”, data engineering, deployment of digital health tools and solutions and health-related matters affected by the internet and the Health Insurance Portability and Accountability Act (HIPAA), as well as private equity investments, mergers, acquisitions, affiliations and joint ventures involving technology, digital health companies, hospitals and physicians. Stephen co-leads the Firm’s Digital Health Practice, which brings together McDermott lawyers from within and outside the Health Industry Advisory Practice Group to develop thought leadership, share information and collaborate on best practices. Stephen served as global head of the Firm’s Health Practice from 2009-2018, and as the Health Practice’s Partner-in-Charge of Health Practice Operations during 2023 and 2024. He has also served on the Firm’s Management, Compensation, Executive and Finance Committees.
- Advised Best Buy Health on its $400M cross-border acquisition of remote Patient Monitoring Company, Current Health
- Advised OMERS Private Equity on healthcare regulatory matters associated with its $900M+ acquisition of Gastro Health
- Advised the American Society of Clinical Oncology on its development and implementation of CancerLinQ, a national initiative aimed at assembling a vast database of usable, searchable, real-world cancer information designed to improve the quality of cancer care for patients, and since sold to ConcertAI
- Chambers USA, Band 1 in Healthcare, 2010-2026
- Best Lawyers in America, Healthcare Law, 2007-2027
- Legal 500 US, 2015-2019
- American Health Lawyers Association
- Jewish Family & Children’s Services, member of the Board of Directors and the Disabilities Committee
- Boston College Law School, JD, cum laude
- Duke University, AB, magna cum laude
- California
- District of Columbia
- Massachusetts
- English

Nicholas Azis
Nicholas (Nick) Azis is a highly experienced corporate lawyer who advises a broad range of publicly owned and privately held clients on mergers and acquisitions transactions, principally in the commodities, energy, technology and manufacturing sectors. He has significant experience in corporate reorganisations and provides day to day corporate counsel to his clients on the application of UK regulation such as the Bribery Act, Criminal Finances Act and Modern Slavery Act on commercial activities in the UK. He also acts as a deputy General Counsel for the firm.
- Represented Irving Oil in the acquisition of the Tedcastle group of companies (operating under the Top Oil brand) in Ireland
- Represented IDEAL Industries Inc. in the sale of its European networks division
- Represented Terminix Global Holdings Inc in the sale of its Norwegian and UK pest control businesses as a condition to its merger with Rentokil Initial PLC
- The Best Lawyers in the United Kingdom, Mergers and Acquisitions Law, 2023-2025
- IFLR1000, Energy and Natural Resources, 2022-2023
- Legal 500 UK, Corporate and Commercial: M&A: lower mid-market, Leading Individual, 2021 and 2024-2025
- University of Law, LLB, First Class Honours
- University of Bristol, BA
- England and Wales
- English
- French
